IL-17 in Severe Asthma. Where Do We Stand? - Archive ouverte HAL Access content directly
Journal Articles American Journal of Respiratory and Critical Care Medicine Year : 2014

IL-17 in Severe Asthma. Where Do We Stand?

(1, 2) , (3, 2) , (2, 1, 4) , (3) , (5, 6) , (1, 2, 4)


Asthma is a major chronic disease ranging from mild to severe refractory disease and is classified into various clinical phenotypes. Severe asthma is difficult to treat and frequently requires high doses of systemic steroids. In some cases, severe asthma even responds poorly to steroids. Several studies have suggested a central role of IL-17 (also called IL-17A) in severe asthma. Indeed, high levels of IL-17 are found in induced sputum and bronchial biopsies obtained from patients with severe asthma. The recent identification of a steroid-insensitive pathogenic Th17 pathway is therefore of major interest. In addition, IL-17A has been described in multiple aspects of asthma pathogenesis, including structural alterations of epithelial cells and smooth muscle contraction. In this perspective article, we frame the topic of IL-17A effects in severe asthma by reviewing updated information from human studies. We summarize and discuss the implications of IL-17 in the induction of neutrophilic airway inflammation, steroid insensitivity, the epithelial cell profile, and airway remodeling.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-02163354 , version 1 (24-06-2019)



Julie Chesne, Faouzi Braza, Guillaume Mahay, Sophie Brouard, Marc Aronica, et al.. IL-17 in Severe Asthma. Where Do We Stand?. American Journal of Respiratory and Critical Care Medicine, 2014, 190 (10), pp.1094-1101. ⟨10.1164/rccm.201405-0859PP⟩. ⟨inserm-02163354⟩
106 View
1 Download



Gmail Facebook Twitter LinkedIn More